Ri Zhao Shi

Researchers are evaluating the effectiveness of zanubrutinib combined with anti-CD20 antibodies compared to lenalidomide plus rituximab (R2) in adults with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). The study aims to measure progression-free survival using independent review committees and established lymphoma response criteria based on PET/CT and CT imaging. Participants will receive zanubrutinib orally either as 160 mg twice daily or 320 mg once daily in continuous 28-day cycles. In the zanubrutinib plus rituximab group, rituximab is given intravenously at 375 mg/m2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 2 to 5, each cycle lasting 28 days. The comparator group receives lenalidomide orally at 20 mg daily on Days 1 to 21 of each 28-day cycle for 12 cycles, plus obinutuzumab intravenously at 1000 mg on Cycle 1 Days 1, 8, 15 and Cycles 2 to 6 Day 1. During the study, participants will undergo imaging assessments such as PET/CT and CT scans to evaluate disease progression. Researchers will monitor treatment response and safety over approximately 78 months. Progression-free survival is the primary outcome, measured by a blinded independent review committee. Participants are expected to have measurable disease and adequate organ function at enrollment, with ongoing assessments to track treatment effects and adverse events.

Researchers are evaluating the use of albumin combined with endovascular treatment in patients who have acute ischemic stroke affecting the anterior circulation. This phase 3, multicenter, open-label clinical trial aims to verify the safety and effectiveness of adding albumin to reperfusion therapy for these patients. The study enrolls adults aged 18 to 80 years who have had a large vessel occlusion stroke and meet specific clinical criteria. Participants are randomly assigned to one of two groups: one group receives albumin together with endovascular therapy, and the other group receives endovascular therapy alone. Albumin is administered intravenously at a dose of 0.5 g/kg (up to 37.5 g) on the first day and then daily on days two, three, and four. All patients receive standard acute stroke treatment and secondary prevention according to current American stroke guidelines. Initial evaluations include brain imaging (CT or MRA) to locate the blockage and check for bleeding, as well as laboratory tests and stroke severity scoring. Throughout the study, vital signs and neurological assessments are recorded. After 90 days from randomization, patients are followed up by telephone to assess recovery using quality of life scales and functional outcomes. The main measure of success is the proportion of patients achieving a good functional status or returning to their baseline level at 90 days. Safety and efficacy are carefully monitored during this period to understand the impact of albumin therapy in this patient population.

Stroke is the second leading cause of death worldwide, with ischemic stroke being the most common type. The current best treatment for acute ischemic stroke is intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) given within 4.5 hours of symptom onset. However, some patients experience stroke progression or early blood vessel reocclusion after thrombolysis, which worsens neurological function and outcomes. This is believed to be caused by increased platelet activation after thrombolysis, which peaks within the first 2 hours. This clinical trial is testing whether starting oral aspirin early after intravenous thrombolysis can improve functional outcomes without causing more bleeding problems. Patients are randomly assigned to receive either 300 mg aspirin tablets or matching placebo tablets as soon as possible after enrollment. If swallowing is difficult, tablets can be crushed and given through a nasogastric tube. Both groups receive best medical management according to guidelines. The study is a Phase 3, multicenter, randomized, placebo-controlled trial. Participants will be followed for 90 days after stroke to measure their functional recovery using the modified Rankin scale (mRS). Researchers will check if patients have a good outcome defined as an mRS score of 0 or 1 at 90 days. During the study, patients undergo assessments including neurological exams and imaging to confirm eligibility and monitor safety. The trial aims to determine if early aspirin treatment after thrombolysis is safe and can help prevent neurological decline and improve recovery.

Researchers are conducting a multicenter, prospective, observational real-world study across 200 hospitals in China to examine treatment patterns for chronic hepatitis B (CHB). The study aims to compare patient outcomes under various therapies to provide evidence-based data that can help optimize CHB treatment and follow-up, with the ultimate goal of advancing a functional cure for chronic hepatitis B. The focus includes monitoring the incidence of hepatocellular carcinoma (HCC) associated with hepatitis B. Participants receive treatments including entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF), or Peginterferon α-2b injection. The study follows both patients currently on these therapies and those initiating or re-initiating Peginterferon α-2b therapy. These treatments are assessed in routine clinical practice settings without intervention from the study team. Throughout the study, patients are monitored from week 4 up to week 240 for the development of HBsAg-associated hepatocellular carcinoma (HCC) and overall HCC incidence. Researchers collect data on treatment effectiveness and safety as part of the observational follow-up. Participants provide informed consent and are observed under real-world conditions to evaluate long-term outcomes and risks associated with chronic hepatitis B and its treatments.

Researchers are evaluating the safety and effectiveness of a Peripheral Scoring Drug-coated Balloon dilation catheter in treating hemodialysis arteriovenous fistula stenosis. This prospective, multi-center, single-arm clinical study involves 328 participants with arteriovenous fistula or graft stenosis who require intervention to improve blood flow during hemodialysis. Participants will be treated with the Dissolve AV Peripheral Scoring Drug-coated Balloon device. After the procedure, follow-up visits occur within 5 days, then at 1 month, 6 months, and later at 12, 18, and 24 months to monitor outcomes. The main measure of effectiveness is the target lesion primary patency (TLPP) at 6 months post-procedure, which assesses how well the treated blood vessel remains open. Throughout the study, participants will undergo evaluations including ultrasound or contrast imaging to assess stenosis severity and blood flow, as well as clinical assessments of symptoms, dialysis adequacy, and venous pressure. Safety and device effectiveness will be monitored at each scheduled visit over a two-year period to ensure comprehensive outcome tracking.